CRM197

Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine Development

Retrieved on: 
Thursday, March 28, 2024
Partnership, CRM197, Therapy, GMP, CDMO, Research, Infection, Primrose, Vaccine

Third parties engaged in developing conjugate vaccines will have access to a seamless solution for vaccine conjugation, manufacturing and supply.

Key Points: 
  • Third parties engaged in developing conjugate vaccines will have access to a seamless solution for vaccine conjugation, manufacturing and supply.
  • “We are excited to announce our partnership with Primrose Bio.
  • By combining our expertise with Primrose's cutting-edge technologies, we aim to revolutionize the landscape of conjugate vaccine development, ultimately benefiting millions worldwide."
  • The partnership signifies a strategic alignment aimed at advancing vaccine development and accessibility for researchers and industry clients.

Ligand’s Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

Retrieved on: 
Thursday, July 27, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, MSD, Vaccine, CRM197, Merck, OPA, Pelican, Ligand

If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.

Key Points: 
  • If approved, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults.
  • Additionally, results from STRIDE-6 demonstrated that V116 was immunogenic for all 21 pneumococcal serotypes in the vaccine among adults who previously received a pneumococcal vaccine at least one year prior to the study.
  • V116 utilizes the CRM197 vaccine carrier protein, which is produced using Ligand’s patent-protected Pelican Expression Technology™ platform.
  • “We are delighted to see Merck’s continued progress with V116 and their pneumococcal conjugate vaccine franchise,” said Todd Davis, CEO of Ligand.

Fina Biosolutions Selects Scorpius BioManufacturing for Production of cGMP CRM197

Retrieved on: 
Thursday, July 27, 2023
CRM197, GSK plc, Partnership, Attenuated vaccine, Business, Escherichia coli, Diphtheria, Scorpius, CDMO, CGMP, Patient, SAN, Serum Institute of India, Vaccine, Tourism

SAN ANTONIO, July 27, 2023 /PRNewswire/ -- Fina Biosolutions has selected Scorpius BioManufacturing , a biologics contract development and manufacturing organization (CDMO), for the production of an E.coli-expressed CRM197 conjugate vaccine carrier protein.

Key Points: 
  • SAN ANTONIO, July 27, 2023 /PRNewswire/ -- Fina Biosolutions has selected Scorpius BioManufacturing , a biologics contract development and manufacturing organization (CDMO), for the production of an E.coli-expressed CRM197 conjugate vaccine carrier protein.
  • "Fina Biosolutions is an innovative biotech company that deserves the responsiveness traditional CDMOs often fail to provide to smaller, more nimble clients.
  • They are exactly the type of partner we envisioned supporting when we founded Scorpius in 2020," said Jeff Wolf, Scorpius' Founder and Executive Chairman.
  • To learn more about Fina Biosolutions' conjugate vaccine technology and services, visit FinaBio.net .

CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research

Retrieved on: 
Monday, April 25, 2022
Nature, DNA, Adenoviridae, HKEX, COVID-19, Meningococcal disease, Research, Life, R, Multilateralism, Group, CRM197, Trial of the century, Technology, Vaccine, Company, Infection, CanSino Biologics, History, Coronavirus, Public health, MCV4, Multimedia, SSE, RNA transfection, Pharmaceutical industry

This is the first major brand refresh of CanSinoBIO since its inception in 2009.

Key Points: 
  • This is the first major brand refresh of CanSinoBIO since its inception in 2009.
  • The blue color represents "technology" and the green color represents "life," embracing and complementing each other to depict the close relationship between technology and human life.
  • Sixty-nine years later, CanSinoBIO continues to uphold the scientific spirit by committing to continuous research and development (R&D) of innovative, high-quality and accessible vaccine products to protect human life.
  • Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to research, production and commercialization of innovative vaccines for China and global public health security.

CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research

Retrieved on: 
Monday, April 25, 2022
Nature, DNA, Adenoviridae, HKEX, COVID-19, Meningococcal disease, Research, Life, R, Multilateralism, Group, CRM197, Trial of the century, Technology, Vaccine, Company, Infection, CanSino Biologics, History, Coronavirus, Public health, MCV4, SSE, RNA transfection, Pharmaceutical industry

This is the first major brand refresh of CanSinoBIO since its inception in 2009.

Key Points: 
  • This is the first major brand refresh of CanSinoBIO since its inception in 2009.
  • The blue color represents "technology" and the green color represents "life," embracing and complementing each other to depict the close relationship between technology and human life.
  • Sixty-nine years later, CanSinoBIO continues to uphold the scientific spirit by committing to continuous research and development (R&D) of innovative, high-quality and accessible vaccine products to protect human life.
  • Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to research, production and commercialization of innovative vaccines for China and global public health security.

Merck Provides Update on FDA Review of Supplemental Biologics License Application for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) for Use in Infants and Children

Retrieved on: 
Friday, April 1, 2022
FDA, Health, Research, Pharmaceutical, Science, Biotechnology, MSD, Life, LinkedIn, Headache, Population, MRK, Anaphylaxis, Patent, 23F, Allergy, Immunocompetence, Merck & Co., Prescription Drug User Fee Act, NYSE, Conjugate vaccine, Medicine, Vaccine, Vaccination, Research, SEC, Myalgia, Cancer, Food, U.S. Securities and Exchange Commission, Private Securities Litigation Reform Act, Security (finance), Diphtheria, Twitter, Breakthrough therapy, Priority review, COVID-19, Regulation of tobacco by the U.S. Food and Drug Administration, CRM197, News, Animal, HIV, Coronavirus, PDUFA, YouTube, Arthralgia, Streptococcus pneumoniae, FDA, Instagram, Fatigue, Patient, Infection, Pharmaceutical industry, Birth control, Facebook, Merck, VAXNEUVANCE (PNEUMOCOCCAL 15-VALENT CONJUGATE VACCINE), MERCK

The FDA requested additional analyses of data from the pediatric studies, which Merck has submitted to the FDA.

Key Points: 
  • The FDA requested additional analyses of data from the pediatric studies, which Merck has submitted to the FDA.
  • In December 2021, Merck announced that the FDA accepted the companys application for VAXNEUVANCE for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age and it was granted Priority Review.
  • VAXNEUVANCE previously received Breakthrough Therapy designation and Priority Review from the FDA for the prevention of invasive pneumococcal disease in children 6 weeks through 17 years of age.
  • Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid.

CanSinoBIO's Convidecia™ Approved as Heterologous Booster in Malaysia and Indonesia

Retrieved on: 
Tuesday, March 22, 2022
SSE, Ministry of Health (Bahrain), CanSino Biologics, Convidecia, Vaccination, National Agency of Drug and Food Control of Indonesia, Group, Clinical trial, Public health, Vaccine, Adenoviridae, Research, Certification, Good manufacturing practice, Ageing, HKEX, Immunology, Omicron, Technology, RNA transfection, COVID-19, Ministry, CRM197, Inhalation, Good, GMP

The MOH Malaysia recommends using Convidecia as a heterologous booster for individuals aged 18 and above who have been administered two doses of inactivated COVID-19 vaccine at least three months prior.

Key Points: 
  • The MOH Malaysia recommends using Convidecia as a heterologous booster for individuals aged 18 and above who have been administered two doses of inactivated COVID-19 vaccine at least three months prior.
  • The BPOM recommends that adults who have received inactivated COVID-19 vaccines opt for either Convidecia or an mRNA vaccine as a booster.
  • In addition to Malaysia and Indonesia, Convidecia has been approved for use as a heterologous booster in China and Argentina in national vaccination programs in February 2022 and November 2021, respectively.
  • Recent studies[1]showed that using Convidecia as a heterologous booster, either through intramuscular injection or inhalation, generated greater neutralizing antibody responses than those induced by the homologous inactivated vaccine booster or heterologous recombinant protein vaccine booster.

Latest Study Shows Advantages of CanSinoBIO's Convidecia™ as Heterologous Booster against Omicron Variant

Retrieved on: 
Monday, March 14, 2022
CRM197, GMT, RNA transfection, CanSino Biologics, GMT K2XX, Infection, Research, Public health, RBD, Vaccination, Inhalation, Omicron, MedRxiv, IQR, Group, HKEX, COVID-19, SSE, Adenoviridae, Biomedical Research, Severe acute respiratory syndrome coronavirus 2, Immunity, Vaccine, Convidecia

The results showed that booster vaccination with either intramuscular injection or inhaled version of Convidecia generated greater neutralizing antibody responses than those induced by the homologous inactivated vaccine booster or heterologous recombinant protein vaccine booster.

Key Points: 
  • The results showed that booster vaccination with either intramuscular injection or inhaled version of Convidecia generated greater neutralizing antibody responses than those induced by the homologous inactivated vaccine booster or heterologous recombinant protein vaccine booster.
  • A heterologous booster with one dose of Convidecia can significantly increase cellular immune protection against the transmission of and infection with the Omicron variant, and effectively prevent severe cases and immune escape.
  • The study showed that boosting with either intramuscular or inhaled version of Convidecia can elicit significantly higher RBD-specific binding antibodies than those induced by recombinant protein vaccine or inactivated vaccine.
  • The study observed an increased neutralizing antibody response against the wild-type SARS-CoV-2 induced by the inhaled version of Convidecia.

Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster

Retrieved on: 
Tuesday, January 11, 2022
Ageing, CoronaVac, Inhalation, Vaccination, Research, SSRN, Safety, Vaccine, RBD, CanSino Biologics, COVID-19, HKEX, Group, CRM197, Severe acute respiratory syndrome coronavirus 2, Public health, Recombinant, SSE, Immunity, Adenoviridae, Serum, RNA transfection, Trial of the century, Delta, Lancet

The results of the study indicated that a heterologous booster with one dose of the Inhalation Convideciafor adults aged 18 years and above, who have received two doses of inactivated COVID-19 vaccine, can induce a higher level of neutralizing antibodies than those with a homogeneous booster of inactivated vaccine.

Key Points: 
  • The results of the study indicated that a heterologous booster with one dose of the Inhalation Convideciafor adults aged 18 years and above, who have received two doses of inactivated COVID-19 vaccine, can induce a higher level of neutralizing antibodies than those with a homogeneous booster of inactivated vaccine.
  • CanSinoBIO's inhaled COVID-19 vaccine provides unique advantages and represents an innovative solution in response to the COVID-19 pandemic.
  • The data on safety results showed that there were fewer cases of adverse events after the heterologous booster of the Inhalation Convideciathan those administered with a homologous booster of inactivated vaccine.
  • The data on immunogenicity showed that the inhaled heterologous booster elicited a significantly higher level of neutralizing antibodies than those with a homogeneous booster of inactivated vaccine.

Latest Study Shows Encouraging Results of CanSinoBIO's Inhaled COVID-19 Vaccine as Heterologous Booster

Retrieved on: 
Tuesday, January 11, 2022
Ageing, CoronaVac, Inhalation, Vaccination, Research, SSRN, Safety, Vaccine, RBD, CanSino Biologics, COVID-19, HKEX, Group, CRM197, Severe acute respiratory syndrome coronavirus 2, Public health, Recombinant, SSE, Immunity, Adenoviridae, Serum, RNA transfection, Trial of the century, Delta, Lancet

The results of the study indicated that a heterologous booster with one dose of the Inhalation Convideciafor adults aged 18 years and above, who have received two doses of inactivated COVID-19 vaccine, can induce a higher level of neutralizing antibodies than those with a homogeneous booster of inactivated vaccine.

Key Points: 
  • The results of the study indicated that a heterologous booster with one dose of the Inhalation Convideciafor adults aged 18 years and above, who have received two doses of inactivated COVID-19 vaccine, can induce a higher level of neutralizing antibodies than those with a homogeneous booster of inactivated vaccine.
  • CanSinoBIO's inhaled COVID-19 vaccine provides unique advantages and represents an innovative solution in response to the COVID-19 pandemic.
  • The data on safety results showed that there were fewer cases of adverse events after the heterologous booster of the Inhalation Convideciathan those administered with a homologous booster of inactivated vaccine.
  • The data on immunogenicity showed that the inhaled heterologous booster elicited a significantly higher level of neutralizing antibodies than those with a homogeneous booster of inactivated vaccine.